表纸
市场调查报告书

溶小体病的治疗:技术和全球市场

Lysosomal Disease Treatments: Technologies and Global Markets

出版商 BCC Research 商品编码 701122
出版日期 内容信息 英文 118 Pages
订单完成后即时交付
价格
Back to Top
溶小体病的治疗:技术和全球市场 Lysosomal Disease Treatments: Technologies and Global Markets
出版日期: 2018年09月10日内容信息: 英文 118 Pages
简介

全球溶小体储积症 (LSD) 治疗市场,预计从2018年的51亿美元,到2023年扩大到76亿美元,其间为8.3年复合成长率 (CAGR) 。

本报告提供全球溶小体储积症 (LSD) 治疗市场相关调查分析,市场概要,市场趋势分析与预测,各市场区隔、各地区的市场分析,法规形势,主要企业简介等相关的系统性信息。

第1章 简介

第2章 摘要和亮点

第3章 市场概要、背景

  • 历史
  • 定义
  • 溶小体
  • 溶小体储积症 (LSD)
    • 最常见的LSD
  • 溶小体储积症的症状
  • 溶小体储积症的诊断
    • 溶小体储积症的治疗
  • 市场动态
    • 市场成长的促进要素
    • 市场成长的阻碍因素
  • 患者支持团体的重要性
  • 更迅速的药物核准的法规选项
  • 溶小体储积症的流行病学

第4章 溶小体储积症的治疗选项

  • 酵素补充疗法 (ERT)
  • 口服基材合成抑制药 (SRT)
  • 药理学性Chaperone疗法 (PCT)

第5章 市场分析:各疾病类型

  • 高雪氏症
  • 法布瑞氏症
  • 庞贝氏症
  • 黏多醣症
  • 其他

第6章 市场分析:各给药途径

  • 口服给药
  • 静脉注射

第7章 市场分析:各最终用途

  • 医院
  • 诊疗所
  • 其他

第8章 市场分析:各治疗类型

  • 酵素补充疗法
  • 基材合成抑制疗法

第9章 市场分析:各地区

  • 北美
  • 欧洲
  • 亚太地区
    • 中国
    • 印度
  • 其他

第10章 企业简介

第11章 附录A:全球LSD学会的清单

第12章 附录B:简称

第13章 附录C:用语

BBC 关于Research

目录
Product Code: PHM183A

Report Highlights:

The global market for lysosomal storage diseases treatment should grow from $5.1 billion in 2018 to reach $7.6 billion by 2023 at a compound annual growth rate (CAGR) of 8.3% for the period of 2018-2023.

Gaucher's diseases as a segment of lysosomal storage diseases treatment market should grow from $1.6 billion in 2018 to reach $2.2 billion by 2023 at a CAGR of 6.2% for the period of 2018-2023.

Fabry diseases as a segment of lysosomal storage diseases treatment market should grow from $1.3 billion in 2018 to reach $2.1 billion by 2023 at a CAGR of 9.6% for the period of 2018-2023.

Report Scope:

The lysosomal storage disease treatment market has been divided by type of indication into: Gaucher's Diseases, Fabry Diseases, Pompe's Syndrome, Mucopolysaccharidosis and more. Mucopolysaccharidosis is further segmented into Hunter syndrome, Hurlers Syndrome and Moriquo syndrome. The market is also segmented by routing of administration into IV and oral. The market has been divided into hospitals, clinics and other facilities into end users by type of treatment into enzyme replacement therapy and substrate reduction therapy. The market has been segmented into North America, Europe, Asia-Pacific and RoW.

Report Includes:

  • 37 data tables and 25 additional tables
  • An overview of the global market for lysosomal disease treatments
  • Analyses of global market trends, with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
  • Segmentation of the global market by cancer therapy indiscation, treatment type, route of administration, end-use, application and geographical region
  • Information on current regulatory environment, and a trend analysis of recent government policies and regulations for lysosomal disease treatments
  • Assessment of lysosomal storage diseases by the accumulated substrate and the profitability of focusing on ultra-orphan diseases
  • Profiles of major players in the industry, including Astellas Pharma, Astrazeneca, Eli Lilly and Co., Merck & Co., Inc., and Novo Nordisk A/S

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Overview and Background

  • History
  • Definition
  • Lysosomes
  • Lysosomal Storage Diseases
    • Most common LSDs
  • Symptoms of Lysosomal Storage Diseases
  • Diagnosis of Lysosomal Storage Diseases
    • Treatments for Lysosomal Storage Diseases
  • Market Dynamics
    • Drivers
    • Restraint
  • Importance of Patient Support Groups
  • Regulatory Options for Faster Drug Approval
  • Epidemiology Lysosomal Storage Disorders

Chapter 4: Treatment Options for Lysosomal Storage Diseases

  • Enzyme Replacement Therapy (ERT)
  • Oral Substrate Reduction Therapy (SRT)
  • Pharmacological Chaperone Therapy (PCT)
  • Gene Therapy

Chapter 5: Market Breakdown by Disease Type

  • Gauchers
    • Diagnosis
    • Treatment
    • Oral Substrate Reduction Therapy (SRT)
  • Fabry Disease
    • Type 1 Classic Phenotype
  • Pompe Disease
    • Causes
    • Treatment
  • Mucopolysaccharidosis (MPS)
    • Hurlers (MPS I)
    • Hunter Syndrome (MPS II)
    • Morquio Syndrome (MPS IV)
  • Others

Chapter 6: Market Breakdown by Route of Administration

  • Oral Route of Administration
  • Intravenous Route of Administration

Chapter 7: Market Breakdown by End Use

  • Hospitals
  • Clinics
  • Others

Chapter 8: Market Breakdown by Treatment Type

  • Enzyme Replacement Therapy Market
  • Substrate Reduction Therapy

Chapter 9: Market Breakdown by Region

  • North America
  • Europe
  • Asia-Pacific
    • China
    • India
  • Rest of the World

Chapter 10: Company Profiles

  • ACTELION PHARMACEUTICALS LTD.
    • Overview
    • Financials
    • Products
    • Recent News and Developments
  • AMICUS THERAPEUTICS
    • Financial
  • ARENA PHARMACEUTICALS INC.
    • Overview
    • Financials
    • Recent News and Developments
  • ASTELLAS PHARMA
    • Overview
    • Financials
    • Recent News and Developments
  • ASTRAZENECA
    • Overview
    • Financials
  • BIOMARIN PHARMACEUTICAL INC.
    • Overview
    • Financials
    • Products
    • Recent News and Developments
  • ELI LILLY AND COMPANY
    • Overview
    • Financials
    • Recent News and Developments
  • LEXICON PHARMACEUTICALS, INC.
  • MERCK & CO., INC.
    • Overview
    • Financials
    • Recent News and Developments
  • NOVO NORDISK A/S
    • Overview
    • Product Areas:
    • Financials
    • Revenues by Business Segment
    • Recent News and Developments
  • SANGAMO THERAPEUTICS, INC.
    • Overview
    • Financials
    • Recent News and Developments
  • SANOFI GENZYME
    • Overview
    • Recent News and Developments
  • SHIRE
    • Overview
    • Financials
    • Recent News and Developments

Chapter 11: Appendix A: Global List of Lysosomal Storage Disease Societies

Chapter 12: Appendix B: Abbreviations

Chapter 13: Appendix C: Glossary of Terms

List of Tables

  • Summary Table: Global Market for Lysosomal Storage Diseases Treatment, by Type, Through 2023
    • Table 1: Major Events in Lysosomal Storage Diseases, 1882-2004
    • Table 2: Types of Lysosomal Storage Diseases
    • Table 3: Most Common LSDs
    • Table 4: Orphan Drug Regulations in Different Countries
    • Table 5: Comparison of Policies in Different Countries
    • Table 6: Orphan Drug Market Exclusivity in Various Countries
    • Table 7: Summary of Selective LSDs Intended for Newborn Screening, Clinical and Biochemistry Features and Comparison of Enzyme Methods
    • Table 8: Recommendations to Overcome the Restraints
    • Table 9: Therapeutic Options and Target Diseases
    • Table 10: Global Market for Gaucher's Disease Treatment, by Region, Through 2023
    • Table 11: Fabry Disease Sign and Symptoms
    • Table 12: Global Market for Fabry Disease Treatment, by Region, Through 2023
    • Table 13: Global Market for Pompe's Disease Treatment, by Region, Through 2023
    • Table 14: Global Market for Mucopolysaccharidosis Disease Treatment, by Region, Through 2023
    • Table 15: Global Market for Hurlers Disease Treatment, by Region, Through 2023
    • Table 16: Global Market for Hunter Disease Treatment, by Region, Through 2023
    • Table 17: Global Market for Morquio Disease Treatment, by Region, Through 2023
    • Table 18: Global Market for Other LSD Treatment, by Region, Through 2023
    • Table 19: Global Market for Lysosomal Storage Diseases Treatment, by Route of Administration, Through 2023
    • Table 20: Global Market for Lysosomal Storage Disease Via Oral Route of Administration, by Region, Through 2023
    • Table 21: Global Market for Lysosomal Storage Diseases Via IV Route of Administration, by Region, Through 2023
    • Table 22: Global Market for Lysosomal Storage Diseases Treatment, by End Use, Through 2023
    • Table 23: Global Market for Lysosomal Storage Diseases in Hospitals, by Region, Through 2023
    • Table 24: Global Market for Lysosomal Storage Diseases in Clinics, by Region, Through 2023
    • Table 25: Global Market for Lysosomal Storage Diseases in Others, by Region, Through 2023
    • Table 26: Global Market for Lysosomal Storage Diseases Treatment, by Types of Therapy, Through 2023
    • Table 27: Approved ERT for LSDs
    • Table 28: Global Market for Lysosomal Storage Diseases in Enzyme Replacement Therapy, by Region, Through 2023
    • Table 29: Global Market for Lysosomal Storage Diseases Treatment in Substrate Reduction Therapy, by Region, Through 2023
    • Table 30: Comparison of Different Countries and Rare Disease Policies
    • Table 31: North American Market for Lysosomal Storage Diseases Treatment, by Type, Through 2023
    • Table 32: European Market for Lysosomal Storage Diseases Treatment, by Type, Through 2023
    • Table 33: Asia-Pacific Market for Lysosomal Storage Diseases Treatment, by Type, Through 2023
    • Table 34: Comparison of South East Asia-Pacific Countries
    • Table 35: Rest of the World Market for Lysosomal Storage Diseases Treatment, by Type, Through 2023
    • Table 36: Actelion Pharmaceuticals: Revenues and R&D Expenditures, Through 2016
    • Table 37: Actelion Pharmaceuticals: Product Developments, 2017
    • Table 38: Amicus Therapeutics: Revenues and R&D Expenditures, Through 2016
    • Table 39: Arena Pharmaceuticals: Revenues and R&D Expenditures, Through 2016
    • Table 40: Arena Pharmaceuticals: Product Developments, 2017
    • Table 41: Astellas Pharma: Revenues and R&D Expenditures, Through 2017
    • Table 42: Astellas Pharma: Product Developments, 2017
    • Table 43: AstraZeneca: Revenues and R&D Expenditures, Through 2016
    • Table 44: AstraZeneca: Revenues, by Country/Region, 2014-2016
    • Table 45: BioMarin Pharmaceutical: Revenues and R&D Expenditures, Through 2016
    • Table 46: BioMarin Pharmaceutical: Product Developments, 2017
    • Table 47: Eli Lilly: Revenues and R&D Expenditures, Through 2016
    • Table 48: Eli Lilly's Revenues: by Country/Region, 2014-2016
    • Table 49: Eli Lilly: Product Developments, 2017
    • Table 50: Merck & Co.: Revenues and R&D Expenditures, Through 2016
    • Table 51: Merck & Co.: Product Developments, 2017
    • Table 52: Novo Nordisk: Revenues and R&D Expenditures, Through 2016
    • Table 53: Novo Nordisk: Revenues, by Business Segment, 2014-2016
    • Table 54: Novo Nordisk: Product Developments, 2017
    • Table 55: Sangamo Therapeutics: Revenues and R&D Expenditures, Through 2016
    • Table 56: Sangamo Therapeutics' Product Developments, 2015-2017
    • Table 57: Sanofi Genzyme: Product Developments, 2016-2017
    • Table 58: Shire: Revenues and R&D Expenditures, Through 2016
    • Table 59: Shire's Product Developments, 2017
    • Table 60: Abbreviations Used in Lysosomal Disease Treatments
    • Table 61: Glossary of Terms Used in Lysosoaml Storage Diseases Treatment Market

List of Figures

  • Summary Figure: Global Market for Lysosomal Storage Diseases Treatment, by Type, 2017-2023
    • Figure 1: Timeline of Lysosomal Storage Diseases
    • Figure 2: Market Dynamics
Back to Top